Roche Holding AG
ROP
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
personal-finance
The US dollar looks overvalued. Should individual investors care?
Some things are a lot more important to professional investors than everybody else.
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,697.50 | 139.10 | -1.57% |
| CAC 40 | 8,080.74 | 66.09 | -0.81% |
| DAX 40 | 25,463.81 | 272.43 | -1.06% |
| Dow JONES (US) | 49,097.06 | 1,101.11 | -2.19% |
| FTSE 100 | 10,452.68 | 98.49 | -0.93% |
| HKSE | 22,435.24 | 406.38 | -1.78% |
| NASDAQ | 23,879.20 | 550.69 | -2.25% |
| Nikkei 225 | 56,967.05 | 2,477.16 | -4.17% |
| NZX 50 Index | 14,102.30 | 144.95 | -1.02% |
| S&P 500 | 7,175.83 | 147.80 | -2.02% |
| S&P/ASX 200 | 8,597.60 | 132.80 | -1.52% |
| SSE Composite Index | 3,521.40 | 56.22 | -1.57% |